Table 6.

Reasons for non-completion of study follow-up by region and by regimen

	North-America (n = 771)		Non North-America (n = 70)
	3HP-DOT* (n = 363)	9H-SAT* (n = 408)	3HP-DOT* (n = 30)	9H-SAT* (n = 40)
Reason	n (%)	n (%)	n (%)	n (%)
Withdrew consent (n = 139)	58 (16.0)	72 (17.6)	6 (20.0)	3(7.5)
Developed active TB (n = 5)†	3 (0.83)	2 (0.49)	—	—
Refusal of further follow-up (n = 7)	4 (1.1)	3 (0.74)	—	—
Lost to follow-up (n = 410)‡	187 (51.5)	194 (47.5)	11 (36.7)	18 (45.0)
Other (n = 147)	56 (15.4)	76 (18.6)	7 (23.3)	8 (20.0)
Missing (n = 133)	55 (15.2)	61 (15.0)	6 (20.0)	11 (27.5)
Total (n = 841)	363 (47.1)	408 (52.8)	30 (42.9)	40 (57.1)

^*3HP-DOT = 3 months of directly observed once-weekly RPT (maximum dose, 900 mg) plus INH (maximum dose, 900 mg); 9H-SAT = 9 months of daily self-administered INH (maximum dose, 300 mg).

^†Classified as 3HP-DOT probable clinical TB in adult (n=2), spine disease (discitis) not characteristic of TB spondylitis (n = 1)and 9H-SAT probable clinical TB in adult (n = 2).

^‡3 participants in the 3HP group and 4 in the 9H group died after month 33, and were lost at the last follow-up evaluation. They were therefore added to the lost to follow-up category.

H, INH = isoniazid; P, RPT = rifapentine; DOT = directlyobserved therapy; SAT = self-administered treatment.